BACKGROUND Gastrointestinal nematodes are parasites that commonly infect dogs, and infections can be subclinical or may cause considerable clinical disease. Some species are zoonotic and may also cause clinical disease in humans. Year-round treatment of dogs is recommended to eliminate existing infections, which also indirectly reduces the potential for subsequent human exposure to zoonotic species. Here we present two studies that evaluated the safety and efficacy of a novel chewable oral tablet containing sarolaner, moxidectin and pyrantel against gastrointestinal nematode infections in dogs presented as veterinary patients in Europe and the USA. METHODS Dogs naturally infected with Toxocara canis, Toxascaris leonina, Ancylostoma caninum and/or Uncinaria stenocephala were enrolled in the European study, and dogs naturally infected with T. canis were enrolled in the USA study. The animals were treated once orally with Simparica Trio™ tablets to provide 1.2-2.4 mg/kg sarolaner, 24-48 µg/kg moxidectin and 5-10 mg/kg pyrantel (as pamoate salt) or with a commercially available product according to the label directions as positive control. Efficacy was based on the post-treatment reduction in geometric mean egg counts (per gram feces) 7 or 10 days after treatment compared to pre-treatment egg counts. RESULTS Simparica Trio™ was well tolerated in both studies. In the European study, geometric mean egg counts for T. canis, T. leonina, A. caninum and U. stenocephala were reduced by ≥ 98.3% in the Simparica Trio™ group and by ≥ 97.4% in the afoxolaner + milbemycin oxime group. In the USA study, geometric mean egg counts for T. canis were reduced by 99.2% in the Simparica Trio™ group and by 98.6% in the ivermectin + pyrantel group. In the USA study, 48 and 10 dogs in the Simparica Trio™ and the ivermectin + pyrantel group, respectively, were co-infected with A. caninum and the reduction in the post-treatment mean fecal egg counts were 98.6% and 74.7%, respectively. CONCLUSIONS A single oral administration of Simparica Trio™ chewable tablets was well tolerated and was effective in the treatment of dogs with naturally occurring gastrointestinal nematode infections presented as veterinary patients in Europe and the USA.

中文翻译：

---

含有sarolaner，moxidectin和pyrantel（Simparica Trio™）的新型口服咀嚼片对在欧洲和美国作为兽医患者的狗的自然获得的胃肠道线虫感染的现场疗效和安全性。

背景技术胃肠道线虫是通常感染狗的寄生虫，并且感染可以是亚临床的或可以引起相当大的临床疾病。一些物种是人畜共患病的，也可能导致人类临床疾病。建议对狗进行全年治疗，以消除现有的感染，这也间接减少了人类随后暴露于人畜共患病物种的可能性。在这里，我们目前进行的两项研究评估了一种新型的可咀嚼的口服片剂，其中含有sarolaner，moxidectin和pyrantel对抗在欧洲和美国作为兽医患者的狗的胃肠道线虫感染。方法在欧洲研究中招募了天然感染了犬弓形虫，Toxascaris leonina，犬十二指肠和/或钩头畸形犬的狗，以及天然感染了T的狗。犬被纳入美国研究。用Simparica Trio™片剂对动物进行一次口服处理，以提供1.2-2.4 mg / kg的sarolaner，24-48 µg / kg的莫昔克丁和5-10 mg / kg的吡咯烷（如棕榈酸盐）或根据市售产品将方向标记为阳性对照。功效基于治疗后7或10天与治疗前相比的几何平均卵数（每克粪便）减少。结果Simparica Trio™在两项研究中均具有良好的耐受性。在欧洲的一项研究中，Simparica Trio™组的犬圆弧菌，莱昂纳氏菌，犬短柄线虫和Stenocephala的几何平均卵数降低了≥98.3％，而阿福索拉纳+ milbemycin肟组降低了≥97.4％。在美国的研究中，犬圆弧菌的平均卵数减少了99。Simparica Trio™组为2％，伊维菌素+吡喃酮组为98.6％。在美国的研究中，Simparica Trio™组和伊维菌素+吡喃酮组分别有48只和10只犬与犬链球菌一起感染，治疗后平均粪便卵数减少了98.6％和74.7％，分别。结论单次口服Simparica Trio™咀嚼片具有良好的耐受性，可有效治疗在欧洲和美国作为兽医患者出现的自然发生的胃肠道线虫感染的狗。